Clinical trials: Cytoreductive Surgery
Acute Kidney Injury, Chemotherapy
Prediction of Kidney Injury After Hyperthermic Intraperitoneal Chemotherapy (HIPEC)* With Machine Learning
Patients undergoing cytoreductive surgery with hyperthermic intraoperative chemotherapy (CRS with HIPEC) are prone to postoperative kidney dysfunction.
- Trial name
- HIPEC (NCT03895606)
- Testing
- Data collection
- Where
- South Korea
- Volunteers
- 57 people
- Sponsor
- Gangnam Severance Hospital
Pseudomyxoma Peritonei, Postoperative Delirium (POD)
Proactive Temperature Management in CRS-HIPEC for Prevention of Delirium
This randomized controlled trial evaluates the efficacy of a proactive Goal-Directed Temperature Management (GDTM) protocol in reducing postoperative delirium among patients undergoing Cytoreductive Surgery (CRS) with…
- Trial name
- NCT07378371
- Testing
- Proactive Goal-Directed Temperature Management, Standard Reactive Temperature Management
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Aerospace Center Hospital
Ovarian Cancer, Ovarian Neoplasms
Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer
The main purpose of this study is to validate a safe dose of atezolizumab with dose-dense paclitaxel and carboplatin when utilized with neoadjuvant chemotherapy and interval cytoreductive surgery followed by maintenance…
- Trial name
- AdORN (NCT03394885)
- Testing
- Atezolizumab, Carboplatin, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Colorectal Carcinomatosis
Inferior Epigastric Lymph Node in Colorectal Carcinosis
In this study, the investigators propose to systematically collect and analyse epigastric lymph nodes during complete cytureductive surgery in patients with colorectal carcinomatosis, in order to define their role in the…
- Trial name
- EpiLyPath (NCT04966715)
- Testing
- Epigastric lymph node biopsy
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Jules Bordet Institute
Pseudomyxoma Peritonei
Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients
The goal of this clinical trial is to evaluate the safety and efficacy of neoadjuvant capecitabine and cyclophosphamide treatment in patients affected by huge Pseudomyxoma peritonei (PMP) (peritoneal cancer index >28).
- Trial name
- REVERSE (NCT06800391)
- Testing
- Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Ovarian Cancer, Primary Peritoneal Cancer
Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer
The OvIP1 study is designed to examine how drug dose and perfusion temperature affect the pharmacokinetics and pharmacodynamics of cisplatin used as (hyperthermic) intraperitoneal chemoperfusion, as an adjunct to surgery, in…
- Trial name
- OvIP1 (NCT02567253)
- Testing
- Cytoreductive surgery, IPEC with Cisplatin (75mg/m²), IPEC with Cisplatin (100mg/m²)
- Where
- Belgium
- Volunteers
- 56 people
- Sponsor
- University Hospital, Ghent
Peritoneal Carcinomatosis
Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
Peritoneal carcinomatosis from advanced gastro-intestinal malignancy has historically been associated with poor overall survival (≤ 12 months) with few treatment options.
- Trial name
- NCT04779554
- Testing
- Mitomycin C, flat dose 40 mg, Mitomycin C, weight-based dose 12.5 mg/m2
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Prakash Pandalai
Fallopian Tube Cancer, Ovarian Cancer
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00331422
- Testing
- carboplatin, paclitaxel, cytoreductive surgery
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer
PROV-MESH: Prophylactic Ovarian Cancer MESH
Incisional hernia is a common complication after midline laparotomy and may significantly impact quality of life, morbidity, and healthcare costs.
- Trial name
- PROV-MESH (NCT07676370)
- Testing
- Prophylactic Mesh Placement, Negative Pressure Wound Therapy (NPWT), Standard Fascial Closure
- Where
- Spain
- Volunteers
- 152 people
- Sponsor
- Hospital Vall d'Hebron
Metastatic Ovarian Carcinoma, Peritoneal Carcinomatosis
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer
Women with history of tumor response insufficient to allow complete cytoreductive surgery after three cycles of previous neoadjuvant systemic carboplatin-paclitaxel chemotherapy will be prospectively recruited in this trial.
- Conditions
- Metastatic Ovarian Carcinoma, Peritoneal Carcinomatosis, Stage III Ovarian Cancer, Stage III Fallopian Tube Cancer
- Trial name
- PIPACOVA (NCT04811703)
- Testing
- Combined PIPAC / IV chemotherapy treatment
- Where
- 6 sites in France
- Volunteers
- 15 people
- Sponsor
- Hospices Civils de Lyon
Recurrent Ovarian Carcinoma
Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection.
- Trial name
- SCENIC (NCT06292286)
- Testing
- Carboplatin or cisplatin, Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar, Bevacizumab or biosimilar
- Where
- Hong Kong
- Volunteers
- 18 people
- Sponsor
- The University of Hong Kong
Ovarian Cancer, Recurrent Ovarian Carcinoma
Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
This novel study was specifically designed for platinum resistant recurrent ovarian cancers and aimed to compare cases who received secondary cytoreductive surgery for isolated recurrence and chemotherapy versus chemotherapy…
- Trial name
- NCT04795596
- Testing
- secondary cytoreductive surgery, Chemotherapy
- Where
- Egypt
- Sponsor
- Menoufia University
Ovarian Neoplasms
Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer
Aim of the Study is to compare two-years disease-free survival of Cytoreductive Surgery (CRS) and Hyperthermic IntraPEritoneal Chemotherapy (HIPEC, CDDP+Paclitaxel) vs CRS alone in Stage IIIC unresectable epithelial tubal/ovarian…
- Trial name
- CHORINE (NCT01628380)
- Testing
- Cytoreductive Surgery and HIPEC, CRS alone
- Where
- 5 sites in Germany, Italy
- Volunteers
- 94 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Lactacidemia and Complications
Lactate and Complications in Cytoreduction Surgery for Peritoneal Carcinomatosis
Serum lactate is a risk factor for postoperative complications in patients undergoing cytoreduction surgery in peritoneal carcinomatosis
- Trial name
- NCT04307654
- Volunteers
- 57 people
- Sponsor
- Hospital General Universitario de Castellón
Ovarian Cancer
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
- Trial name
- OVHIPEC-2 (NCT03772028)
- Testing
- cisplatin
- Where
- 28 sites in United States, Denmark and 5 more
- Volunteers
- 538 people
- Sponsor
- The Netherlands Cancer Institute
Colorectal Cancer
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01167725
- Testing
- bevacizumab, cetuximab, FOLFIRI regimen
- Where
- 2 sites in United States
- Volunteers
- 340 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Ovarian Cancer
Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients
At present, the treatment of recurrent ovarian cancer after PARP inhibitor therapy is quite challenging, and there is no research on the application of hyperthermic intraperitoneal chemotherapy(HIPEC) for the above-mentioned…
- Trial name
- NCT06544460
- Testing
- Secondary cytoreduction, Hyperthermic intraperitoneal chemotherapy
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Fudan University
Advanced Ovarian Cancer
SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS
The treatment of choice in advanced ovarian cancer is a cytoreductive surgery combined with chemotherapeutic treatment. This complex and aggressive surgery is associated with high postoperative complication rates that may result…
- Trial name
- SOPHIE (NCT04862325)
- Testing
- Multimodal Prehabilitation
- Where
- 2 sites in Spain
- Volunteers
- 158 people
- Sponsor
- Hospital Clinic of Barcelona
Pseudomyxoma Peritonei
One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei
The goal of this clinical trial is to compare the efficacy and safety of one versus three sessions of hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) for patients with pseudomyxoma peritonei…
- Trial name
- NCT07328737
- Testing
- One HIPEC session, Three HIPEC sessions
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Lung Cancer
Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy
The goal of this clinical research study is to find the highest tolerated dose of heated cisplatin that can be given to patients with lung tumors. The safety of this drug will also be studied.
- Trial name
- NCT01998529
- Testing
- Cisplatin, Amifostine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center